Malaria surveillance -- United States, 2007 by Arguin, Paul M. et al.
Department Of Health And Human Services
Centers for Disease Control and Prevention
Surveillance Summaries April 17, 2009 / Vol. 58 / No. SS-2
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr




William L. Roper, MD, MPH, Chapel Hill, NC, Chairman
Virginia A. Caine, MD, Indianapolis, IN
David W. Fleming, MD, Seattle, WA
William E. Halperin, MD, DrPH, MPH, Newark, NJ
Margaret A. Hamburg, MD, Washington, DC
King K. Holmes, MD, PhD, Seattle, WA
Deborah Holtzman, PhD, Atlanta, GA
John K. Iglehart, Bethesda, MD
Dennis G. Maki, MD, Madison, WI
Sue Mallonee, MPH, Oklahoma City, OK
Patricia Quinlisk, MD, MPH, Des Moines, IA
Patrick L. Remington, MD, MPH, Madison, WI
Barbara K. Rimer, DrPH, Chapel Hill, NC
John V. Rullan, MD, MPH, San Juan, PR
William Schaffner, MD, Nashville, TN
Anne Schuchat, MD, Atlanta, GA
Dixie E. Snider, MD, MPH, Atlanta, GA
John W. Ward, MD, Atlanta, GA
The MMWR series of publications is published by the Coordinating 
Center for Health Information and Service, Centers for Disease 
Control and Prevention (CDC), U.S. Department of Health and 
Human Services, Atlanta, GA 30333.
Suggested Citation: Centers for Disease Control and Prevention. 
[Title]. MMWR 2009;58(No. SS-#):[inclusive page numbers].
Centers for Disease Control and Prevention
Richard E. Besser, MD
(Acting) Director
Tanja Popovic, MD, PhD
Chief Science Officer
James W. Stephens, PhD
Associate Director for Science
Steven L. Solomon, MD
Director, Coordinating Center for Health Information and Service
Jay M. Bernhardt, PhD, MPH
Director, National Center for Health Marketing
Katherine L. Daniel, PhD
Deputy Director, National Center for Health Marketing
Editorial and Production Staff
Frederic E. Shaw, MD, JD
Editor, MMWR Series
Susan F. Davis, MD
(Acting) Assistant Editor, MMWR Series
Robert A. Gunn, MD, MPH
Associate Editor, MMWR Series
Teresa F. Rutledge
Managing Editor, MMWR Series
David C. Johnson
(Acting) Lead Technical Writer-Editor
Catherine B. Lansdowne, MS
Project Editor
Martha F. Boyd




Kim L. Bright, MBA




Introduction  ............................................................................. 2
Methods  .................................................................................. 2
Data Sources ......................................................................... 2
Definitions  ............................................................................. 3
Laboratory Diagnosis of Malaria  ............................................ 3
Results  ..................................................................................... 4
General Surveillance  ............................................................. 4
Plasmodium Species  .............................................................. 4
Region of Acquisition and Diagnosis  ....................................... 4
Imported Malaria by Resident Status  ....................................... 4
Estimated Relative Case Rates Among U.S. Residents  ................ 4
Interval Between Arrival in the United States and Illness  ............ 5
Imported Malaria Among U.S. Military Personnel  .................... 5
Prophylaxis Use Among U.S. Civilians  .................................... 5
Malaria Infection After Recommended Prophylaxis Use  ............ 5
Clinical Complications ............................................................ 6
Purpose of Travel  ................................................................... 6
Malaria by Age  ..................................................................... 6
Malaria During Pregnancy  ..................................................... 6
Selected Malaria Case Reports ................................................ 7
Discussion................................................................................. 7
References .............................................................................. 10
Vol. 58 / SS-2 Surveillance Summaries 1
Corresponding author: Sonja Mali, MPH, Division of Parasitic Diseases, 
National Center for Zoonotic, Vector-Borne, and Enteric Diseases, CDC, 
4770 Buford Hwy., N.E., MS F-22, Atlanta, GA 30341. Telephone: 
770-488-7757; Fax: 770-488-4465; E-mail: smali@cdc.gov. 
Malaria Surveillance — United States, 2007
Sonja Mali, MPH
Stefanie Steele, RN, MPH
Laurence Slutsker, MD, MPH 
Paul M. Arguin, MD 
Division of Parasitic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases 
Abstract 
Problem/Condition: Malaria in humans is caused by intraerythrocytic protozoa of the genus Plasmodium. These 
parasites are transmitted by the bite of an infective female Anopheles mosquito. The majority of malaria infections in 
the United States occur among persons who have traveled to areas with ongoing malaria transmission. In the United 
States, cases can occur through exposure to infected blood products, congenital transmission, or local mosquitoborne 
transmission. Malaria surveillance is conducted to identify episodes of local transmission and to guide prevention rec-
ommendations for travelers. 
Period Covered: This report summarizes cases in persons with onset of illness in 2007 and summarizes trends during 
previous years. 
Description of System: Malaria cases confirmed by blood film, rapid diagnostic tests, or polymerase chain reaction are 
mandated to be reported to local and state health departments by health-care providers or laboratory staff members. 
Case investigations are conducted by local and state health departments, and reports are transmitted to CDC through 
the National Malaria Surveillance System, the National Notifiable Diseases Surveillance System, and direct CDC con-
sultations. Data from these reporting systems are the basis for this report. 
Results: CDC received reports of 1,505 cases of malaria among persons in the United States, including one transfusion-
related case and one fatal case, with onset of symptoms in 2007; 1,564 cases were reported for 2006. P. falciparum, P. 
vivax, P. malariae, and P. ovale were identified in 43.4%, 20.3%, 2.0%, and 3.5% of cases, respectively. Nine patients 
(0.6%) were infected by two or more species. The infecting species was unreported or undetermined in 30.2% of 
cases. Based on estimated volume of travel, the highest estimated relative case rates of malaria among travelers occurred 
among those returning from countries in West Africa. Of 701 U.S. civilians who acquired malaria abroad and for whom 
chemoprophylaxis information was known, 441 (62.9%) reported that they had not followed a chemoprophylactic drug 
regimen recommended by CDC for the area to which they had traveled. Twenty-four cases were reported in pregnant 
women; none had adhered to a complete prevention drug regimen. One death was reported in a person infected with 
P. vivax.
Interpretation: No significant change in the number of malaria cases occurred from 2006 to 2007. No change was 
observed in the proportion of cases by species causing the infection. U.S. civilians traveling to countries in West Africa 
had the highest estimated relative case rates. In the majority of reported cases, U.S. civilians who acquired infection abroad 
had not adhered to a chemoprophylaxis regimen that was appropriate for the country where they acquired malaria. 
Public Health Actions: Persons at risk for malaria infection should take one of the recommended chemoprophylaxis 
regimens appropriate for the region of travel and use personal protection measures to prevent mosquito bites. Any person 
who has been to a malarious area and who subsequently has a fever or influenza-like symptoms should seek medical 
care immediately and report their travel history to the clinician; investigation should always include blood-film tests 
for malaria with immediately available results. Malaria infections can be fatal if not diagnosed and treated promptly. 
Recommendations concerning malaria prevention are available from CDC at http://wwwn.cdc.gov/travel/content-
diseases.aspx#malaria or by calling the CDC Malaria 
Hotline (telephone: 770-488-7788). Recommendations 
concerning malaria treatment are available at http://www.
cdc.gov/malaria/diagnosis_treatment/treatment.htm or 
by calling the Malaria Hotline. 
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Introduction 
Malaria in humans is caused by infection with one or more 
of several species of Plasmodium (i.e., P. falciparum, P. vivax, 
P. ovale, P. malariae, and occasionally other Plasmodium spe-
cies). The infection is transmitted by the bite of an infective 
female Anopheles species mosquito. P. falciparum and P. vivax 
species cause the most infections worldwide. P. falciparum is 
the species that most commonly causes severe, potentially fatal 
malaria. Worldwide, an estimated 350–500 million clinical 
cases and approximately 1 million deaths caused by malaria 
occur annually, primarily among children aged <5 years living 
in sub-Saharan Africa (1). P. vivax and P. ovale have dormant 
liver-stage parasites, which can reactivate and cause malaria 
several months or years after the infecting mosquito bite. P. 
malariae can result in long-lasting infections that, if untreated, 
can persist asymptomatically in the human host for years, even 
a lifetime (1). P. knowlesi, a parasite of Old World monkeys, 
has been documented as a cause of human infections and 
some fatalities in Southeast Asia; investigations are ongoing 
to determine the extent of transmission to humans (2,3). A 
total of 49% of the world population lives in areas where 
malaria is transmitted (i.e., 109 countries in parts of Africa, 
Asia, the Middle East, Eastern Europe, Central and South 
America, Caribbean, and Oceania). Before the 1950s, malaria 
was endemic throughout the southeastern United States; an 
estimated 600,000 cases occurred in the United States in 1914 
(4). During the late 1940s, a combination of improved housing 
and socioeconomic conditions, environmental management, 
vector-control efforts, and case management was successful at 
interrupting malaria transmission in the United States. Since 
then, malaria case surveillance has been maintained to detect 
locally acquired cases that could indicate the reintroduction of 
transmission and to monitor patterns of resistance to antima-
larial drugs. Anopheline mosquitoes remain seasonally present 
in all states and territories except Hawaii. 
The majority of reported malaria cases diagnosed each 
year in the United States are imported from regions where 
malaria transmission is known to occur, although congenital 
infections and infections resulting from exposure to blood 
or blood products are also reported in the United States. In 
addition, a limited number of cases are occasionally reported 
that might have been acquired through local mosquitoborne 
transmission (5). 
State and local health departments and CDC investigate 
malaria cases acquired in the United States, and CDC analyzes 
data from reported cases to detect trends in acquisition. This 
information is used to guide malaria prevention recommenda-
tions for international travelers. 
The signs and symptoms of malaria illness vary, but the major-
ity of patients have fever. Other common symptoms include 
headache, back pain, chills, increased sweating, myalgia, nau-
sea, vomiting, diarrhea, and cough. The diagnosis of malaria 
should always be considered for persons with these symptoms 
who have traveled to an area with known malaria transmission. 
Malaria also should be considered in the differential diagnosis 
of persons who have fever of unknown origin, regardless of their 
travel history. Untreated P. falciparum infections can rapidly 
progress to coma, renal failure, pulmonary edema, and death. 
This report summarizes malaria cases reported to CDC among 
persons with onset of symptoms in 2007. 
Methods 
Data Sources 
Malaria case data are reported to the National Malaria 
Surveillance System (NMSS) and the National Notifiable 
Diseases Surveillance System (NNDSS) (6). Although both 
systems rely on passive reporting, the numbers of reported 
cases might differ because of differences in collection and 
transmission of data. A substantial difference between the data 
collected in these two systems is that NMSS receives more 
detailed clinical and epidemiologic data regarding each case 
(e.g., information concerning the area to which the infected 
person has traveled). Malaria cases can be reported to CDC 
through NMSS, NNDSS, or a direct consultation with CDC; 
cases identified through these various paths are compared and 
compiled, duplicates are eliminated, and cases are analyzed. 
This report presents data on the aggregate of cases reported to 
CDC through all reporting systems. 
Cases of malaria confirmed by blood film, a rapid diagnos-
tic test (RDT), or polymerase chain reaction (PCR) among 
civilians and military personnel are identified by health-care 
providers or laboratories.* Each confirmed malaria case is 
reported to local or state health departments and to CDC on 
a uniform case-report form that contains clinical, laboratory, 
and epidemiologic information. CDC reviews all report forms 
when received and requests additional information from the 
reporting provider or state if necessary (e.g., when no recent 
travel to a malarious country is reported). Other cases are 
reported by telephone to CDC directly by health-care provid-
ers, usually when they are seeking assistance with diagnosis or 
treatment. Information regarding cases reported directly to 
CDC is shared with relevant state health departments. All cases 
that have been reported as acquired in the United States are 
* To confirm malaria diagnosed by blood films from questionable cases and to 
obtain appropriate treatment recommendations, contact either the state or local 
health department or CDC’s Malaria Hotline (telephone: 770-488-7788).
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investigated further, including all induced and congenital cases 
and possible introduced or cryptic cases. Information derived 
from uniform case report forms is entered into a database and 
analyzed annually. 
An estimated case rate for each country was determined using 
estimates of travel volume for U.S. travelers to each country 
where cases of malaria were acquired and the number of cases 
among U.S. travelers attributable to each country. Data used 
to estimate country-specific relative case rates were extrapo-
lated from World Tourism Organization estimates of annual 
numbers of U.S. travelers to specified countries (7). Estimated 
relative case rates were determined by dividing the individual 
country-specific case rates by the median individual country-
specific case rate.
Definitions 
The following definitions are used in this report: 
U.S. residents:•	  Persons living in the United States; 
includes both civilians and U.S. military personnel, regard-
less of legal citizenship. 
U.S. civilians:•	  U.S. residents, excluding U.S. military 
personnel.
Foreign residents:•	  Persons who have resident status in a 
country other than the United States. 
Laboratory criteria for diagnosis:•	  Demonstration of 
malaria parasites on blood film, RDT, or PCR. 
Confirmed case:•	  Symptomatic or asymptomatic infection 
that occurs in a person in the United States or one of its 
territories who has laboratory-confirmed (by microscopy, 
PCR, or RDT that is subsequently confirmed by micros-
copy or PCR) malaria parasitemia, regardless of whether 
the person has had previous episodes of malaria while 
in other countries. A subsequent episode of malaria is 
counted as an additional case if the indicated Plasmodium 
species differs from the initially identified species. A sub-
sequent episode of malaria occurring in a person while 
in the United States could indicate a relapsing infection 
or treatment failure resulting from drug resistance if the 
indicated Plasmodium species is the same species identi-
fied previously. 
This report also uses terminology derived from the recom-
mendations of the World Health Organization (8). Definitions 
of the following terms are included for reference: 
Autochthonous malaria:•	
Indigenous. –  Mosquitoborne transmission of malaria in 
a geographic area where malaria occurs regularly.
Introduced. –  Mosquitoborne transmission of malaria 
from a person with an imported case in an area where 
malaria does not occur regularly. 
Imported malaria:•	  Malaria acquired outside a specific 
area. In this report, imported malaria cases are those 
acquired outside the United States and its territories. 
Induced malaria: •	 Malaria acquired through artificial 
means (e.g., by blood transfusion, organ transplantation, 
or using shared syringes). 
Relapsing malaria: •	 Recurrence of malaria after the dis-
ease has been apparently cured. True malaria relapses are 
caused by reactivation of dormant liver-stage parasites 
(hypnozoites) found in P. vivax and P. ovale.
Cryptic malaria: •	 A case of malaria for which epidemio-
logic investigations fail to identify a plausible mode of 
acquisition (primarily cases identified in countries where 
malaria is not endemic). 
Laboratory Diagnosis of Malaria 
The early and prompt diagnosis of malaria requires that 
physicians obtain a travel history from every febrile patient. 
Malaria should be included in the differential diagnosis of 
every febrile patient who has traveled to a malarious area. If 
malaria is suspected, a Giemsa-stained film of the patient’s 
peripheral blood should be examined for parasites as soon as 
possible. Thick and thin blood films must be prepared correctly 
because diagnostic accuracy depends on blood-film quality 
and examination by experienced laboratory personnel (9). 
Some reference laboratories and health departments have the 
capacity to perform PCR diagnosis of malaria, although PCR 
is generally reserved for cases for which blood-film diagnosis 
of malaria or species determination is inadequate. PCR results 
are also often not available quickly enough to be useful in the 
initial diagnosis of a patient with malaria. 
An RDT, BinaxNOW Malaria, which detects circulating 
malaria-specific antigens, became available for use in the United 
States on June 13, 2007. The test is the first malaria RDT 
authorized for use in the United States and is only approved for 
use by hospital and commercial laboratories, not by individual 
clinicians or the general public. Use of RDTs in the United 
States can decrease the amount of time required to determine 
whether a patient is infected with malaria but does not elimi-
nate the need for the standard tests (10). Positive and negative 
RDTs must be confirmed by microscopy or PCR. RDTs are 
generally less sensitive than blood films and do not quantify 
malaria parasites (11).
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Results 
General Surveillance 
For 2007, CDC received 1,505 reports of cases of malaria 
occurring among persons in the United States and its territories. 
A total of 734 cases occurred among U.S. residents, 263 cases 
among foreign residents and 508 cases among persons with 
unknown resident status. Of the 734 cases reported among 
U.S. residents, 50.1% were among blacks, 27.2% among 
whites, 10.9% among Asians, and 4% among Hispanics; 67% 
of the U.S. resident cases were among males.
The 1,505 cases reported in 2007 is not significantly different 
from the 1,564 cases reported in 2006 (9) (Table 1) (chi-square 
test; p = 0.25). After a significant increase in cases from 2003 
to 2004 (chi-square test; p = 0.002), the number of malaria 
cases appears to have plateaued beginning in 2004; during 
2004–2007, no statistically significant change occurred in the 
number of reported cases (chi-square test; p = 0.21).  
Plasmodium Species 
Of the 1,505 cases reported in 2007, the infecting species 
of Plasmodium was identified and reported in 1,051 (69.8%) 
cases. P. falciparum and P. vivax accounted for the majority of 
infections and were identified in 62.2% and 29.0% of infected 
persons with species identified, respectively. The number of 
reported cases of P. falciparum and P. vivax remained stable 
during 2005–2007 (Table 2). Among 983 cases for which both 
the region of acquisition and the infecting species were known, 
P. falciparum accounted for 85.1% of infections acquired in 
Africa, 45.4% in the Americas, 18.2% in Oceania, and 10.7% 
in Asia (Table 3). Infections attributed to P. vivax accounted 
for 3.9% acquired in Africa, 52.7% in the Americas, 77.3% 
in Oceania, and 83.2% in Asia. 
Region of Acquisition and Diagnosis 
All cases were reported as imported cases, except for one 
transfusion-related case. Of 1,155 imported cases for which 
the region of acquisition was known, 744 (64.4%) were 
acquired in Africa, 253 (21.9%) in Asia, 131 (11.3%) in the 
Americas, and 27 (2.3%) in Oceania. Countries in West Africa 
accounted for 545 (73.3%) cases acquired in Africa, and India 
accounted for 151 (59.7%) cases acquired in Asia. In the 
Americas, 12 (9.2%) cases were acquired in North America, 
all of which were acquired in Mexico. A combined 99 (78.6%) 
cases were acquired in Central America and the Caribbean 
(Belize, Dominican Republic, El Salvador, Guatemala, Haiti, 
Honduras, Nicaragua, and Panama), of which 66% of the cases 
were acquired in the Caribbean. Twenty (17.3%) cases were 
acquired in South America (Brazil, Guyana, French Guiana, 
Peru, and Suriname). Information regarding region of acquisi-
tion was missing for 349 (23.2%) imported cases (Table 3). 
In the United States, six jurisdictions accounted for 50.7% 
of the reported cases: New York City (n = 233), California (n 
= 157), Texas (n = 136), New York (n = 93), New Jersey (n = 
77), and Maryland (n = 67) (Figure 1). Compared with 2006, 
the states and regions with the most significant change in 
reported malaria burden in 2007 were New York City, Georgia, 
and Alaska. The number of cases reported in New York City 
increased from 174 cases in 2006 to 233 cases in 2007. Cases 
in Georgia decreased by almost half, from 90 in 2006 to 46 
in 2007, and Alaska reported a significant decrease from 23 
cases (all among military personnel) in 2006 to two cases in 
2007. No cases from Alaska among military personnel were 
documented in 2007. 
Imported Malaria by Resident Status 
Of 997 imported malaria cases among persons with known 
resident status, 734 (73.6%) occurred among U.S. residents, 
and 263 (26.4%) occurred among residents of other countries. 
Of the 734 imported malaria cases among U.S. residents, 476 
(64.9%) were acquired in Africa, 143 (19.5%) were acquired in 
Asia, and 75 (10.2%) were acquired in Central American and 
Caribbean regions (Table 4). Of the 263 imported cases among 
foreign residents, 167 (63.5%) were acquired in Africa. Among 
the 167 foreign residents who acquired malaria in Africa and 
for whom purpose of travel was known, 114 (68.3%) reported 
being recent immigrants or refugees, and 21 (12.6%) reported 
visiting friends and relatives in the United States. A total of 61 
cases were in foreign residents who traveled from Tanzania and 
Burundi to the United States; reason for travel was known for 
58 persons, among whom 57 were reported as being recent 
immigrants or refugees, and one was reported as visiting friends 
and relatives. In 2006, no foreign cases were reported from 
Tanzania or Burundi (9).
Estimated Relative Case Rates Among 
U.S. Residents 
Using estimates of travel volume for U.S. travelers to each 
country from which cases of malaria were acquired and the 
number of cases among U.S. travelers attributable to each 
country, a case rate was estimated for each country. In 2007, 
the countries with the lowest estimated case rates of malaria 
among U.S. travelers were China and Thailand (Figure 2). 
Other countries with low estimated relative case rates included 
Mexico, Vietnam, and South Africa. In many of these coun-
tries, malaria risk areas are localized in small geographic areas 
of the country. Countries with estimated relative case rates 
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in the middle range included India, Honduras, Angola, and 
Pakistan, which have more homogenous malaria transmis-
sion throughout the country. Estimated relative case rates 
were highest in West African countries and Oceania, includ-
ing Republic of the Congo, Benin, Papua New Guinea, and 
Solomon Islands. These high estimated case rates likely reflect 
not only widespread transmission areas but also higher trans-
mission intensity (1). 
Interval Between Arrival in the 
United States and Illness 
Both the 1) interval between the date of arrival in the United 
States and onset of illness and 2) infecting Plasmodium species 
were known for 771 (51.2%) of the imported malaria cases 
(Table 5). Symptoms began before arrival in the United States 
in 78 (10.1%) persons and after arrival in 693 (89.9%) persons. 
Clinical malaria occurred <30 days after arrival in 398 (80.1%) 
of the 497 of persons with P. falciparum infections and in 74 
(35.9%) of the 206 persons with P. vivax infections (Table 5). 
Six (0.8%) of the 771 persons became ill with a P. vivax infec-
tion >1 year after returning to the United States. 
Imported Malaria Among U.S. 
Military Personnel 
In 2007, a total of 33 cases of imported malaria were reported 
among U.S. military personnel. Nineteen persons reported 
travel to Afghanistan, and 10 reported travel to South Korea; 
the remaining four persons reported travel to Iraq and two 
unspecified countries in Africa. Information on infecting 
species was known for 25 cases; all cases were P. vivax. Of 
these 25 cases, 15 were among persons who reported having 
taken the appropriate primary chemoprophylactic drug; four 
reported taking the recommended primaquine for presump-
tive antirelapse therapy, and five patients reported adherence 
to the prescribed drug regimen. These cases were reported by 
state health departments and do not include all cases reported 
through malaria surveillance activities conducted by the U.S. 
Department of Defense.
Prophylaxis Use Among U.S. Civilians 
Information concerning chemoprophylaxis use and travel 
area was known for 646 (92.2%) of the 701 U.S. civilians who 
had imported malaria. Of these 646 persons, 205 (31.7%) had 
taken chemoprophylaxis. Of the 205 persons who reported 
taking malaria chemoprophylaxis, 53 (25.9%) had not taken 
a CDC-recommended drug for the area visited, and 143 
(69.8%) had taken a CDC-recommended medication. Data 
for the specific drug taken was missing for the remaining 
nine (4.4%) travelers. A total of 66 (46.2%) patients tak-
ing CDC-recommended chemoprophylaxis reported having 
taken mefloquine, 42 (29.4%) doxycycline, and 27 (18.9%) 
atovaquone/proguanil; four patients (2.8%) who had traveled 
only in areas where chloroquine-resistant malaria has not been 
documented reported having taken chloroquine. Four patients 
took a combination of two CDC-recommended malaria pro-
phylactics for the specific travel region. 
Malaria Infection After Recommended 
Prophylaxis Use 
A total of 143 U.S. civilians contracted malaria after taking 
a recommended antimalarial drug for chemoprophylaxis. Of 
these, 43 (30.1%) reported complete adherence with the drug 
regimen, and 85 (59.4%) reported nonadherence; adherence 
was unknown for the remaining 15 (10.5%). Information 
regarding infecting species was available for 113 (79%) patients 
who had taken a recommended antimalarial drug and unde-
termined for the remaining 30 patients. 
Cases Caused by P. vivax or P. ovale 
Of the 143 patients who had malaria diagnosed after rec-
ommended chemoprophylaxis use, 39 (27.3%) had cases that 
were caused by P. vivax, and 12 (8.4%) had cases caused by P. 
ovale. Of the 51 total cases of P. vivax or P. ovale, 42 (82.3%) 
occurred >45 days after arrival in the United States. These cases 
were consistent with relapsing infections and do not indicate 
primary prophylaxis failures. Information on four cases was 
insufficient to assess a relapse infection because of missing data 
regarding symptom onset or return date. A total of five cases 
occurred <45 days after the patient returned to the United 
States; all were caused by P. vivax. Four of the five patients 
did not adhere to their malaria chemoprophylaxis regimen. 
The patient who contracted malaria but reported adherence 
to the chemoprophylaxis regimen had traveled to Papua New 
Guinea and had taken atovaquone/proguanil for malaria 
chemoprophylaxis. Possible explanations for this case include 
inappropriate dosing, unreported nonadherence, malabsorp-
tion of the drug, an early relapse from hypnozoites established 
at the start of this trip, or emerging parasite resistance. 
Cases Caused by P. falciparum or 
P. malariae 
Sixty of the 143 patients who had malaria diagnosed after 
recommended chemoprophylaxis use included 48 cases of P. 
falciparum and 12 of P. malariae. Of the 48 P. falciparum cases, 
all except two cases were acquired in Africa; one was acquired in 
Vietnam and one in India. Forty-two (87.5%) patients reported 
nonadherence to the antimalarial drug regimen, and three 
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persons had no adherence information available. Three (6.3%) 
patients who had all contracted malaria and had traveled to 
Africa reported adherence with antimalarial chemoprophylaxis; 
one patient took doxycycline, one patient took atovaquone/
proguanil, and one took mefloquine. Of the 12 P. malariae 
cases, 10 were acquired in Africa, and one was acquired in 
Asia (Indonesia). Six of the patients reported nonadherence 
to the antimalarial drug regimen, and two had no adherence 
information available. The remaining four patients reported 
drug regimen adherence; two took mefloquine, and two took 
atovaquone-proguanil
Cases of Mixed Species Infection
Of the 143 patients who had taken a recommended malaria 
chemoprophylaxis, two reported a mixed Plasmodium species 
infection. One patient who traveled to Nigeria acquired a 
mixed infection of P. falciparum and P. ovale, and one patient 
who traveled to Indonesia acquired a mixed infection of P. 
falciparum and P. vivax. Both patients reported taking meflo-
quine for malaria chemoprophylaxis; however, neither patient 
adhered completely to the drug regimen. 
Clinical Complications
Clinical complications associated with malaria were reported 
for 358 (23.8%) of the total 1,505 reported cases. One case was 
fatal. Although patients can have multiple clinical complica-
tions associated with malaria, the largest proportion (53.4%) of 
patients experienced anemia (hemoglobin <11 g/dL or  hema-
tocrit <33%). Of the 358 cases with clinical complications, 57 
(15.9%) cases were classified as severe malaria, because one or 
more of the following manifestations were reported: cerebral 
malaria, renal failure, acute respiratory distress syndrome 
(ARDS), jaundice, or >5% parasitemia. Severe anemia (hemo-
globin <7 g/dL) is also a characteristic of severe malaria (12); 
however, because data for severe anemia are not collected on the 
surveillance form, the percentage of severe malaria cases might 
have been higher.† Of the 57 patients with severe malaria, 
four (7%) reported taking chemoprophylaxis; however, none 
reported complete adherence to the drug regimen. Of the 57 
patients with severe malaria cases, seven were treated using an 
investigational new drug protocol for intravenous artesunate; 
all seven patients recovered after treatment. 
Purpose of travel 
Purpose of travel to areas where malaria is endemic was 
reported for 599 (85.4%) of the 701 U.S. civilians with 
imported malaria. Though travelers could report multiple rea-
sons for travel, the largest proportion (62.8%) was persons who 
had visited friends or relatives in malarious areas; the second 
and third highest proportions (10.2% and 8.5%) were per-
sons who had traveled as tourists or missionaries, respectively 
(Table 6). Proportions of various reasons for travel remained 
stable during 2005–2007.
Malaria by Age 
Among the 1,464 cases among patients for whom age was 
known, 295 (20.2%) cases occurred in persons aged <18 years, 
1,115 (76.2%) in persons aged 18–64 years, and 54 (4.6%) in 
persons aged >65 years. Although the majority of cases occur in 
persons aged 18–64 years, pediatric cases are of particular inter-
est because the preventive care of most children is controlled 
by parents or guardians. Of the 295 (20.2%) cases among 
persons aged <18 years, 100 (33.9%) cases occurred among 
U.S. civilian children, 105 (35.6%) cases among children of 
foreign citizenship, and for 90 (30.5%) children, resident 
status was unknown. 
Seventy-one (71.0%) of the cases among U.S. civilian 
children for whom country of exposure was known were 
attributable to travel to Africa. Of the 100 cases among U.S. 
civilian children, two (2.0%) children were aged <24 months, 
22 (22.0%) were aged 24–59 months, 41 (41.0%) were aged 
5–12 years, and 35 (35.0%) were aged 13–17 years. Of the 87 
children for whom reason for travel was known, 73 (83.9%) 
were reported as visiting friends and relatives; the remaining 
14 cases were attributed to tourist, missionary, and student 
travel. Thirty-one (33.3%) of the 93 children for whom 
chemoprophylaxis information was known were reported as 
having taken chemoprophylaxis, of whom 28 (90.3%) had 
taken an appropriate regimen; however, eight (28.6%) reported 
complete adherence.
Malaria During Pregnancy 
A total of 24 cases of malaria were reported among pregnant 
women in 2007, representing 4.5% of cases among all women. 
Fourteen (58.3%) of the 24 cases occurred among U.S. civilian 
pregnant women; 21 of these patients reported travel to Africa, 
and three reported travel to Central and South American coun-
tries. Thirteen women reported visiting friends and relatives, 
and one reported missionary-related travel. Of the 14 cases of 
malaria reported among U.S. civilian pregnant women, three 
(21.4%) women reported taking malaria chemoprophylaxis. 
One woman reported taking an appropriate medication; how-
ever, she did not complete the drug regimen. No information 
was available on the birth outcomes of these women.† Data on severe anemia (hemoglobin <7 mg/dL) will be reported in subsequent 
malaria surveillance summaries.
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Selected Malaria Case Reports
Malaria Associated with Blood transfusion 
One case of induced malaria, caused by blood transfusion in 
the United States, was reported in 2007. A black woman aged 
25 years with transfusion-dependent sickle cell disease and no 
previous travel history was admitted to a Houston, Texas, hos-
pital on August 12, 2007, with complaints of abdominal pain. 
Treatment was provided for sickle cell crisis. On August 16, 
2007, the woman became febrile and was evaluated for causes 
of fever. On August 20, 2007, P. falciparum malaria with 16% 
parasitemia was diagnosed, and quinidine and doxycycline were 
administered. A retrospective review of blood samples obtained 
on hospital admission revealed that the woman was parasitemic 
on the date of admission. The patient tolerated quinidine well 
and by August 24, 2007, her physician reported resolution of 
parasitemia. However, on August 28, 2007, the patient, who 
was still hospitalized, developed ARDS and acute renal failure, 
requiring mechanical ventilation and hemodialysis. After pro-
longed hospitalization, she recovered and was discharged. 
During the year before admission, the woman had 66 units 
of red blood cells transfused; her most recent transfusions had 
occurred on June 12, 2007, and July 18, 2007. All of the units 
that she had received during June 12–July 18 had come from 
the same blood distribution facility. The hospital’s transfusion 
services department was contacted to initiate an investigation 
of the donors of the units and identify the infected donor, thus 
preventing additional transfusion-related infections. Serologic 
testing using indirect immunofluoresence antibody identified 
one donor with elevated titers of antibodies to malaria consis-
tent with previous malaria infection at an indeterminate time. 
All other donors’ serologic tests were negative. The implicated 
donor was located and questioned regarding malaria history. 
The donor reported immigrating to the United States from 
Nigeria in 2001 and indicated that he had not traveled abroad 
since that time. The donor reported that in 1988, he was hos-
pitalized for a severe febrile illness that was presumed to be 
a malaria infection. He did not recall the infecting species or 
the treatment provided. Investigators explained to the donor 
that his donated blood was likely to be the source of a malaria 
infection in another patient. He understood the findings but 
chose not to undergo any type of malaria therapy because he 
did not feel ill; however, he understood that he should be alert 
for any future episodes. The implicated donor was counseled 
not to donate blood until 3 years after undergoing an appro-
priate malaria therapy. 
Imported Malaria Possibly Associated with 
organ transplantation
On January 18, 2007, a man aged 53 years returned to 
California after a 3-week trip to Pakistan for a kidney trans-
plant; he did not take malaria chemoprophylaxis before his 
trip. During his stay in Pakistan, the man reported spending 
most of his time indoors. The transplant surgery was per-
formed on January 7, 2007; the transplanted kidney came 
from India. During the transplant surgery, no transfusions 
were administered. On January 25, 2007, the man developed 
a fever and sought medical attention. Infection with P. vivax 
was diagnosed. Although the patient might have acquired the 
infection naturally in Pakistan, the kidney transplant procedure 
might have been the source. 
Death Attributed to Malaria 
One death attributable to malaria was reported in 2007. A 
man aged 67 years from India was visiting the United States 
to attend a wedding. He had a history of type 2 diabetes mel-
litus and hyperlipidemia. On October 17, 2007, the man was 
admitted to a U.S. hospital with fever, and P. vivax malaria 
infection was diagnosed. He was treated with quinine sulfate 
and doxycycline and subsequently had a negative blood smear. 
However, the man then developed respiratory failure and 
ARDS, which eventually resulted in severe hypoxia. The man 
developed oliguric renal failure and multisystem organ failure. 
He died on November 21, 2007. 
Discussion
A total of 1,505 cases of malaria were reported to CDC for 
2007, which is not significantly different from the number of 
cases reported in 2006. The number of cases reported with 
no information regarding residence status or clinical findings 
decreased from 634 in 2006 to 508 in 2007 (9). Excluding 
cases with no information on residence status, the percentage 
of U.S. resident cases during 2000–2007 remained stable. 
During 2002–2007, the proportion of cases from Asia 
increased. The number of cases acquired in a specific region 
can be affected by many factors, including the amount of 
transmission occurring in the region, adherence to preventive 
measures (including mosquito avoidance and chemoprophy-
laxis) by travelers, the style of travel that occurs in that country 
(e.g., business or adventure travel), and the volume of travel 
to those countries. 
Of the 1,504 imported cases, 508 (33.8%) cases did not have 
information on residential status. In addition, 350 (23.3%) 
cases did not have information describing travel history. High 
numbers of cases with no reported residential and clinical infor-
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mation compromises the ability of the data to accurately reflect 
trends in malaria surveillance in the United States. Continued 
vigilance is needed by local and state health departments, 
health-care providers, and other health personnel in providing 
essential information regarding malaria cases when submitting 
cases through the various reporting systems to CDC.
Malaria cases acquired in Africa continue to account for 
the largest number of U.S. cases acquired from a specific 
region. The West African region accounts for almost 74% of 
the cases acquired in the continent; however, the number of 
cases acquired in Tanzania and Burundi increased. In 2006, 
only eight cases were acquired from Tanzania, and no persons 
with a malaria infection reported travel to or from Burundi 
(9). In 2007, a combined total of 61 cases were acquired in 
either Tanzania or Burundi. Among these, 57 persons were 
identified as resettling refugees or immigrants as their reason 
for travel to the United States. 
CDC recommends presumptive treatment of P. falciparum 
malaria in refugees who are from areas where malaria is endemic 
before entering the United States to resettle. To ensure adequate 
presumptive treatment, the treatment regimen must be com-
pleted no sooner than 3 days before departure to the United 
States (13). This strategy decreases risk for symptoms, severe 
complications, or death associated with a malaria infection that 
could occur after arriving in the United States. Because refugees 
might settle in areas where access to health care is difficult to 
obtain or health-care providers are not familiar with malaria 
diagnosis or treatment, treating possible malaria infections in 
refugees before they immigrate to the United States is optimal 
to prevent ongoing infections from progressing to severe disease 
after arrival in the United States. Presumptive treatment also 
can reduce the risk for malaria reintroduction in the United 
States because the malaria vector, the female Anopheles mos-
quito, is found throughout the continental United States.
The International Organization for Migration (IOM) is 
an intergovernmental agency that evaluates most refugees 
bound for the United States and provides treatment for cer-
tain infectious diseases. To reduce the incidence of malaria 
among refugees after they arrive in the United States, IOM 
administered presumptive malaria treatment against P. falci-
parum to Burundi refugees resettling from Tanzania. In 2005, 
CDC recommended artemisinin-based combination therapy 
(ACT) as presumptive P. falciparum treatment for refugees 
resettling to the United States from sub-Saharan Africa (14). 
However, until July 2007, IOM continued to implement 
sulfadoxine-pyrimethamine (SP) treatment for malaria to 
refugees before arrival in the United States; P. falciparum infec-
tions in sub-Saharan Africa have considerable resistance to SP 
(15). Therefore, SP resistance is a possible explanation for the 
increase of cases in Burundi refugees who immigrated to the 
United States in 2007. In response to such cases, IOM is now 
implementing ACT treatment as presumptive P. falciparum 
treatment for refugees resettling in the United States (14). 
A total of 7,545 Burundian refugees from Tanzania resettled 
to the United States during 2007–2008 (16). Health-care 
providers in the United States caring for refugees resettling 
from malaria-endemic regions should remain aware of the 
possibility of malaria in this population, regardless of previ-
ous treatment.
One reason malaria surveillance is conducted is to moni-
tor for prophylaxis failures that might indicate emergence of 
drug resistance. However, approximately 82% of imported 
malaria cases among U.S. residents for whom prophylaxis 
use was known occurred among persons who were not tak-
ing prophylaxis, were taking prophylaxis but not the regimen 
recommended for the region to which they were traveling, or 
were taking a recommended prophylactic regimen incorrectly. 
The majority of patients for whom appropriate prophylaxis was 
reported and who did not have a relapsing infection reported 
nonadherence with the recommended regimen or provided 
insufficient information to determine whether they adhered to 
an appropriate antimalarial chemoprophylaxis regimen. In the 
small subset of patients who reported choosing and adhering 
to the recommended prophylactic drug regimen, subsequent 
malaria might have been a result of malabsorption of the anti-
malarial drug or emerging drug resistance. Because CDC does 
not routinely evaluate blood drug levels among patients with 
malaria who report adherence with a recommended regimen, 
determining whether adherence reporting is inaccurate, the 
antimalarial drug was malabsorbed, or the patient was experi-
encing emerging drug resistance is not possible. No conclusive 
evidence exists to indicate a single national or regional source of 
infection among this group of patients or the failure of a par-
ticular chemoprophylactic regimen. Health-care providers who 
suspect chemoprophylaxis failure should contact CDC quickly, 
which will enable CDC to measure patient antimalarial blood 
drug levels and assess the parasite in vitro for genetic resistance 
characteristics to evaluate for possible drug resistance. 
Severe malaria is characterized by one or more of the follow-
ing clinical complications: prostration, impaired consciousness 
or coma, respiratory distress, seizures, shock, ARDS, jaundice, 
severe anemia, acute renal failure, disseminated intravascular 
coagulation, acidosis, hemoglobinuria, and >5% parasitemia 
(17). Intravenous quinidine gluconate, principally used as an 
antiarrhythmic medicine, also has antimalarial properties and 
is the only parenteral drug approved by the Food and Drug 
Administration for treatment of severe malaria that is avail-
able in the United States. However, quinidine has cardiotoxic 
effects and has become less available in U.S. hospitals with the 
advent of newer antiarrhythmic drugs (18,19). Since 2000, 
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the World Health Organization has recommended artemisi-
nins such as artesunate rather than quinidine for treatment of 
severe malaria; artesunate has been used outside the United 
States for many years (17). On June 21, 2007, CDC’s investi-
gational new drug (IND) protocol for intravenous artesunate 
became effective, allowing the use of intravenous artesunate 
for the treatment of severe malaria. The medication is stocked 
at eight quarantine stations around the United States and can 
be shipped quickly when needed. Precise guidelines must be 
followed and eligibility requirements must be met to enroll a 
patient in the treatment protocol. Artesunate is provided free 
of charge to hospitals on request and on an emergency basis 
by the CDC Drug Service or by one of the CDC quarantine 
stations. Physicians who administer the drug to patients must 
notify CDC of any resulting adverse effects and comply with 
the IND protocol (20). To enroll a patient with severe malaria 
in this treatment protocol, health-care providers should call 
CDC’s Malaria Hotline (Table 7). 
As in previous years, the majority of malaria cases in 2007 
were among persons who traveled to visit friends and relatives. 
Foreign-born U.S. civilians need to be aware that acquired 
immunity wanes quickly when exposure to malaria is inter-
rupted and that they should take prophylaxis when returning 
to malarious areas. In addition, children of foreign-born U.S. 
civilians who are born in the United States have no immunity 
to malaria and are vulnerable to infection (21). In this report, 
approximately three fourths of the children who were visiting 
friends and relatives and contracted malaria had not been 
taking any chemoprophylaxis or had been taking an incorrect 
medication for chemoprophylaxis.
Twenty-four cases were reported in pregnant women, which 
is a 41% increase from 2006. Among the 14 U.S. civilian 
women who were pregnant and contracted malaria, three 
(21.4%) women reported taking chemoprophylaxis, and none 
of these three completely adhered to the drug regimen. The 
proportion of pregnant women taking chemoprophylaxis is 
lower than the percentage of total U.S. civilians with malaria 
who took chemoprophylaxis. Malaria during pregnancy 
poses a high risk for both maternal and perinatal morbidity 
and mortality (22). Pregnant women should be counseled to 
avoid travel to malarious areas. If deferral of travel is impos-
sible, pregnant women should be informed that the risks for 
malaria greatly outweigh those associated with prophylaxis, and 
chemoprophylaxis should be used. Information for pregnant 
women is available at http://www.cdc.gov/malaria/travel/
drugs_pregnant_public.htm.
Appropriate chemoprophylaxis, promptly seeking medical 
care if symptoms develop, and consideration of malaria in the 
differential diagnosis of fever in a traveler who has returned 
to the United States will help ensure malaria is properly man-
aged and controlled in the United States. In addition, because 
induced malaria infections are possible, health professionals 
and blood donation and collection staff members must be 
attentive and thorough in their blood deferment protocols. 
FDA screening guidelines indicate that residents of countries 
where malaria is not endemic who then travel to areas where 
malaria is endemic should not be accepted as blood donors until 
1 year after their departure from the malarious area. Former 
residents of areas where malaria is endemic should be deferred 
from blood donation until 3 years after their departure from 
the malarious area. Persons who receive a diagnosis of malaria 
should not donate blood until 3 years after treatment, during 
which time they must have remained asymptomatic (23). 
Signs and symptoms of malaria are often nonspecific, but 
fever usually is present. Other symptoms include headache, 
chills, increased sweating, back pain, myalgia, diarrhea, nausea, 
vomiting, and cough. Prompt diagnosis requires that malaria 
be included in the differential diagnosis of illness in a febrile 
person with a history of travel to a malarious area. Clinicians 
should ask all febrile patients for a travel history, including 
international visitors, immigrants, refugees, migrant laborers, 
and other international travelers. 
Prompt treatment of suspected malaria is essential because 
persons with P. falciparum infection are at risk for experienc-
ing life-threatening complications soon after onset of illness. 
Ideally, therapy for malaria should be initiated immediately 
after the diagnosis has been made. Treatment should be 
determined on the basis of the infecting Plasmodium species, 
the probable geographic origin of the parasite, the parasite 
density, and the patient’s clinical status (22). If a diagnosis of 
malaria is suspected and cannot be confirmed, or if a diagnosis 
of malaria is confirmed but species determination is not pos-
sible, antimalarial treatment should be initiated that is effective 
against P. falciparum. Resistance of P. falciparum to chloroquine 
is worldwide, with the exception of a limited number of geo-
graphic regions (e.g., Mexico and Central America); therefore, 
therapy for presumed P. falciparum malaria should include a 
drug effective against such resistant strains (24). 
Health-care providers should be familiar with prevention, 
recognition, and treatment of malaria and are encouraged to 
consult appropriate sources for malaria prevention and treat-
ment recommendations (Table 7). Physicians seeking assistance 
with the diagnosis or treatment of patients with suspected or 
confirmed malaria should call CDC’s Malaria Hotline (Table 7) 
during regular business hours; during evenings, weekends, and 
holidays, physicians should call CDC’s Emergency Operations 
Center (Table 7) and ask the staff member to page the person 
on call for the Malaria Branch. These resources are intended 
for use by health-care providers only. 
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Detailed recommendations for preventing malaria are avail-
able to the general public online at http://www.cdc.gov/travel/
diseases.htm/malaria. In addition, CDC biannually publishes 
recommendations in Health Information for International Travel 
(commonly referred to as The Yellow Book) (1), which is avail-
able for purchase from Elsevier (http://www.elsevierhealth.com 
or telephone: 800-545-2522); the publication is also available 
and updated more frequently on the CDC Travelers’ Health 
site at http://wwwn.cdc.gov/travel. Additional information on 
malaria prevention recommendations is available through the 
online CDC malaria map application (http://www.cdc.gov/
malaria/risk_map). The application is an interactive map that 
provides information on malaria risk throughout the world. 
Users can search for or browse through countries, cities, and 
place names and obtain information about malaria and recom-
mended malaria prevention medications in particular locations. 
The malaria map application complements resources currently 
available on the CDC Travelers’ Health website. 
CDC provides assistance for diagnostic parasitology through 
DPDx, CDC’s Division of Parasitic Diseases diagnostic web-
site. DPDx (available at http://www.dpd.cdc.gov/dpdx) pro-
vides free Internet-based laboratory diagnostic assistance (i.e., 
telediagnosis) to laboratorians and pathologists who are investi-
gating suspected parasitic disease cases, such as malaria. Digital 
images captured from diagnostic specimens can be submitted 
by e-mail for consultation. Telediagnosis assistance from CDC 
is available during regular business hours (Monday–Friday, 
8 a.m.–4:30 p.m. EST). Because laboratories can transmit 
images to CDC and obtain a rapid response (average time: 
minutes to several hours) to their inquiries, DPDx allows 
efficient diagnosis of challenging cases and rapid dissemination 
of information. As of January 2007, approximately 49 public 
health laboratories in 46 states and Puerto Rico had the abil-
ity to perform telediagnosis. Implementation of telediagnosis 
at public health laboratories is supported by CDC, including 
training of personnel in digital imaging techniques and diag-
nostic identification of parasites. The DPDx Internet site is 
CDC’s reference for the telediagnosis of parasitic diseases and 
also serves as an online guide for diagnostic parasitology.  The 
DPDx website contains reference material with images, text, 
and videos on approximately 100 different species of parasites, 
covering information on laboratory diagnosis, geographic dis-
tribution, clinical features, treatment, and life cycles.
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FIGURE 1. Number of malaria cases,* by state in which the disease was diagnosed — United States, 2007
* N = 1,505. 
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* Using estimates of travel volume for U.S. travelers to each country from which cases of malaria were acquired and the number of cases among U.S. travel-
ers attributable to each country, a case rate was estimated for each country.  Data used to estimate country-specific relative case rates were extrapolated 
from World Tourism Organization estimates of annual numbers of U.S. travelers to specified countries (7). Relative case rates were determined by dividing 
the individual country-specific case rates by the median individual country-specific case rate. The number of cases of malaria among U.S. civilian travelers 
attributable to each country is displayed next to the country name in parentheses. 
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1977 11 233 237 0 481
1978 31 270 315 0 616
1979 11 229 634 3 877
1980 26 303 1,534 1 1,864
1981 21 273 809 0 1,103
1982 8 348 574 0 930
1983 10 325 468 0 803
1984 24 360 632 0 1,016
1985 31 446 568 0 1,045
1986 35 410 646 0 1,091
1987 23 421 488 0 932
1988 33 550 440 0 1,023
1989 35 591 476 0 1,102
1990 36 558 504 0 1,098
1991 22 585 439 0 1,046
1992 29 394 481 6 910
1993 278 519 453 25 1,275
1994 38 524 370 82 1,014
1995 12 599 461 95 1,167
1996 32 618 636 106 1,392
1997 28 698 592 226 1,544
1998 22 636 361 208 1,227
1999 55 833 381 271 1,540
2000 46 827 354 175 1,402
2001 18 891 316 158 1,383
2002 33 849 272 183 1,337
2003 36 767 306 169 1,278
2004 32 775 282 235 1,324
2005 36 870 297 325 1,528
2006 50 736 217 561 1,564
2007 33 701 263 508 1,505
* A case was defined as symptomatic or asymptomatic illness that 
occurs in the United States or one of its territories in a person who has 
laboratory-confirmed malaria parasitemia (as confirmed by microscopy 
or polymerase chain reaction), regardless of whether the person had 
previous attacks of malaria while in other countries. A subsequent malaria 
infection occurring in a person is counted as an additional case if the 
demonstrated Plasmodium species differs from the initially identified spe-
cies or if the infection is indicated as a relapsing infection caused by the 
same Plasmodium species identified previously. A subsequent malaria 
infection occurring as a result of a drug resistance failure is not counted 
as an additional case. 
† The increase in persons with unknown civil status that began in the 1990s 
might be a result of a change in the surveillance form.
TABLE 2. Number of malaria cases, by Plasmodium species — 




No. (%) No. (%) No. (%)
P. falciparum 742 (48.6) 613 (39.2) 654 (43.4)
P. vivax 337 (22.1) 275 (17.6) 305 (20.3)
P. malariae 54 (3.5) 46 (2.9) 30 (2.0)
P. ovale 38 (2.5) 47 (3.0) 53 (3.5)
Mixed 12 (0.8) 10 (0.6) 9 (0.6)
Undetermined 345 (22.6) 573 (36.3) 454 (30.2)
Total 1,528 (100) 1,564 (100) 1,505 (100)
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TABLE 3. Imported malaria cases, by country of acquisition and Plasmodium species — United States, 2007
Country of acquisition P. falciparum P. vivax P. malariae P. ovale Unknown Mixed Total
Africa 541 25 28 37 108 5 744
Angola 1 0 0 0 0 0 1
Benin 5 0 0 0 0 0 5
Burkina Faso 4 0 0 0 0 0 4
Burundi 11 0 0 0 2 0 13
Cameroon 14 3 1 1 4 0 23
Central African Republic 1 0 0 0 0 0 1
Congo, Republic of the 3 0 1 1 0 0 5
Côte d’Ivoire 22 0 0 0 2 0 24
Egypt 1 0 0 0 0 0 1
Equatorial Guinea 1 0 0 0 1 0 2
Ethiopia 0 4 0 0 3 0 7
Gabon 2 0 0 0 0 0 2
Gambia 6 0 0 0 0 0 6
Ghana 97 2 2 5 14 0 120
Guinea 13 0 2 2 1 0 18
Kenya 11 2 1 1 5 0 20
Liberia 32 2 1 2 9 0 46
Madagascar 0 0 0 0 1 0 1
Malawi 3 0 0 0 0 0 3
Mali 10 0 0 0 3 0 13
Mozambique 4 1 0 0 3 0 8
Nigeria 171 4 8 17 30 4 234
Rwanda 2 0 0 0 0 0 2
Senegal 13 0 0 0 1 0 14
Sierra Leone 17 0 1 1 5 0 24
Somalia 0 1 0 0 0 0 1
South Africa 1 0 0 0 0 0 1
Sudan 4 1 1 0 3 0 9 
Tanzania 37 1 1 2 6 1 48
Togo 4 0 0 0 0 0 4
Uganda 19 3 7 2 7 0 38
West Africa, unspecified 10 0 0 0 0 0 10
East Africa, unspecified 1 0 0 0 1 0 2
Central Africa, unspecified 0 0 0 0 1 0 1
Africa, unspecified 21 1 2 3 6 0 33
Asia 23 179 2 7 38 4 253
Afghanistan 0 22 0 0 4 0 26
Bangladesh 0 1 0 0 0 0 1
Burma (Myanmar) 2 4 0 0 1 0 7
Cambodia 1 1 0 0 0 0 2
China 0 2 0 0 0 0 2
India 13 106 1 3 25 3 151
Indonesia 3 3 1 0 4 1 12
Iraq 0 4 0 0 0 0 4
Korea (South) 0 12 0 0 3 0 15
Malaysia 0 1 0 0 0 0 1
Pakistan 1 9 0 4 1 0 15
Philippines 1 1 0 0 0 0 2
Saudi Arabia 0 1 0 0 0 0 1
Thailand 0 10 0 0 0 0 10
Vietnam 1 0 0 0 0 0 1
Yemen 1 1 0 0 0 0 2
Asia, unspecified 0 1 0 0 0 0 1
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TABLE 4. Number of imported malaria cases among U.S. 







No. (%) No. (%) No. (%)
Africa 476 (64.9) 167 (63.5) 643 (64.5)
Asia 143 (19.5) 77 (29.3) 220 (22.1)
Central America 
  and the Caribbean 75 (10.2) 8 (3.0) 83 (8.3)
South America 13 (1.8) 0 (0) 13 (1.3)
North America 5 (0.6) 4 (1.5) 9 (0.9)
Oceania 20 (2.7) 3 (1.2) 23 (2.3)
Unknown† 2 (0.3) 4 (1.5) 6 (0.6)
Total 734 (100) 263 (100) 997 (100)
* Persons for whom U.S. or foreign status is not known are excluded.
† Region of acquisition is unknown.
TABLE 3. (Continued) Imported malaria cases, by country of acquisition and Plasmodium species — United States, 2007
Country of acquisition P. falciparum P. vivax P. malariae P. ovale Unknown Mixed Total
Central America and the Caribbean 47 41 0 1 10 0 99
Belize 0 0 0 0 1 0 1
Dominican Republic 10 0 0 0 1 0 11
El Salvador 0 1 0 0 0 0 1
Guatemala 0 11 0 0 1 0 12
Haiti 29 1 0 0 4 0 34
Honduras 5 25 0 1 1 0 32
Nicaragua 1 1 0 0 2 0 4
Panama 2 2 0 0 0 0 4
North America 0 9 0 0 3 0 12
Mexico 0 9 0 0 3 0 12
South America 3 8 0 1 8 0 20
Brazil 0 7 0 0 4 0 11
Guyana 0 0 0 0 1 0 1
French Guiana 0 0 0 1 0 0 1
Peru 2 0 0 0 2 0 4
Suriname 1 0 0 0 0 0 1
South America, unspecified 0 1 0 0 1 0 2
Oceania 4 17 0 1 5 0 27
Papua New Guinea 3 15 0 1 5 0 24
Solomon Islands 0 2 0 0 0 0 2
Oceania, unspecified 1 0 0 0 0 0 1
Unknown 35 26 0 6 282 0 349
Total 653 305 30 53 454 9 1,504*
* One case that was transfusion related was not included as an imported case.
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TABLE 7. Sources for malaria prophylaxis, diagnosis, and treatment recommendations
Type of 
information Source Availability Telephone number, website, or e-mail address
Prophylaxis CDC’s Traveler’s Health website 
(includes online access to Health 
Information for International Travel)
24 hours/day http://www.cdc.gov/travel
Prophylaxis Health Information for International 
Travel (The Yellow Book)
Order from: 
Elsevier, Health Sciences Division  
Order Fulfillment 
11830 Westline Industrial Dr. 
St. Louis, MO 63146
800-545-2522 or  
http://www.elsevier.com
Prophylaxis CDC malaria map application 24 hours/day http://www.cdc.gov/malaria/risk_map
Diagnosis CDC Division of Parasitic Diseases 
diagnostic website (DPDx: Laboratory 
Identification of Parasites of Public 
Health Concern)
24 hours/day http://www.dpd.cdc.gov/dpdx
Diagnosis CDC Division of Parasitic Diseases 
diagnostic  CD-ROM (DPDx)




Treatment* CDC Malaria Branch 8:00 A.M.–4:30 P.M. EST,  
Monday–Friday
770-488-7788* (CDC Malaria Hotline)
Treatment* CDC Malaria Branch 4:30 P.M.–8:00 A.M. EST,  weekdays;  
all day weekends and holidays 
770-488-7100* (This is the number for the CDC 
Emergency Operations Center. Ask staff member 
to page the person on call for the Malaria Branch.) 
http://www.cdc.gov/malaria/diagnosis_treatment/
treatment.htm 
* Telephone number is for health-care professionals only.
TABLE 6. Number of imported malaria cases among U.S. 
civilians, by purpose of travel at time of acquisition — United 
States, 2007
Category for purpose of travel*
Imported cases
No. (%)
Visiting friends and relatives 376 (62.8)
Tourism 61 (10.2)
Missionary or dependent 51 (8.5)
Business representative 47 (7.8)
Student or teacher 29 (4.8)
Peace Corps volunteer 6 (1.0)
Air crew or sailor 1 (0.2)
Other/mixed purpose 26 (4.3)
Unknown 102 (17.0)
* Percentages do not equal 100% because travelers can identify multiple 
reasons for purpose of travel.
TABLE 5. Number of imported malaria cases, by interval between date of arrival in the United States and onset of illness and by 
Plasmodium species* — United States, 2007
Interval (days)
P. falciparum P. vivax P. malariae P. ovale Mixed Total
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
<0† 62 (12.5) 13 (6.3) 1 (3.7) 2 (6.2) 0 (0) 78 (10.1)
0–29 398 (80.1) 74 (35.9) 14 (51.9) 10 (31.2) 8 (88.9) 504 (65.4)
30–89 22 (4.4) 44 (21.3) 8 (29.6) 2 (6.3) 0 (0) 76 (9.8)
90–179 6 (1.2) 33 (16.1) 1 (3.7) 11 (34.4) 1 (1.1) 52 (6.7)
180–364 6 (1.2) 36 (17.5) 2 (7.4) 5 (15.6) 0 (0) 49 (6.4)
>365 3 (0.6) 6 (2.9) 1 (3.7) 2 (6.3) 0 (0) 12 (1.6)
Total 497 (100) 206 (100) 27 (100) 32 (100) 9 (100) 771 (100.0)
* Persons for whom Plasmodium species, date of arrival in the United States, or date of onset of illness is unknown are not included.
† Onset of illness before arrival in the United States.
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